title: Alterations of B lymphocyte Fc gamma R II expression and ligand binding capacity induced by various activators.
abstract: Murine B lymphocytes cultured with F(ab')2 anti-mouse mu or delta lost (85%) the capacity to bind antigen-IgG antibody complexes as assessed by flow microfluorometry. Anti-mu-induced loss of binding of complexes was concentration, time, and temperature dependent, reversible, and not due to decreased expression of the receptor because binding of monoclonal anti-Fc gamma R II to B lymphocytes cultured with anti-mu was unaffected. Activation of PKC and elevation of [Ca2+]i obtained by culturing B lymphocytes with the combination of PMA and Ca2+ ionophore induced a similar loss of binding of Cx. Since stimulation of B lymphocytes with anti-mu also activates PKC and elevates [Ca2+]i, these changes may be involved in the anti-mu-induced alterations in the binding of complexes to Fc gamma R II. In contrast to the effects of other activators, LPS caused increased expression (threefold) of B lymphocyte Fc gamma R II as measured by the binding of both complexes and monoclonal anti-Fc gamma R II. Thus, different B lymphocyte activators have distinct effects on Fc gamma R II expression or ligand binding capacity and can thereby affect Fc gamma R II-generated regulatory signals.
authors.affiliation: Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: G
authors.initials: G
authors.lastname: Laszlo
authors.forename: H B
authors.initials: HB
authors.lastname: Dickler
mesh_terms: D000818:Animals; D000936:Antigen-Antibody Complex / Q000378:metabolism; D000943:Antigens, Differentiation / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D004640:Emetine / Q000494:pharmacology; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D007148:Immunoglobulin mu-Chains / Q000276:immunology; D066298:In Vitro Techniques; D015847:Interleukin-4 / Q000494:pharmacology; D008213:Lymphocyte Activation; D051379:Mice; D008811:Mice, Inbred DBA; D011947:Receptors, Antigen, B-Cell / Q000276:immunology; D011961:Receptors, Fc / Q000378:metabolism*; D017452:Receptors, IgG; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000936:Antigen-Antibody Complex; D000943:Antigens, Differentiation; D000949:Histocompatibility Antigens Class II; C024138:I-E-antigen; D007148:Immunoglobulin mu-Chains; D011947:Receptors, Antigen, B-Cell; D011961:Receptors, Fc; D017452:Receptors, IgG; D015847:Interleukin-4; D000001:Calcimycin; D003513:Cycloheximide; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium; D004640:Emetine